T2 Star Magnetic Resonance Imaging and Biomarker Blood Testing to Predict the Change and Progress of Malignant Gliomas

Part of paid clinical trials in Iowa City, Iowa.

Sponsor
John M. Buatti
Study ID
NCT07447531
Status
Recruiting
Apply to this trial

Conditions

  • Malignant Glioma

Eligibility Criteria

Sex
ALL
Age
21 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • T2 (Observed)-Weighted Imaging — PROCEDURE
    Undergo T2\* MRI
  • Biospecimen Collection — PROCEDURE
    Undergo blood sample collection
  • Magnetic Resonance Imaging — PROCEDURE
    Undergo standard MRI

Study Details

This clinical trial studies whether T2 star (T2\*) magnetic resonance imaging (MRI) and biomarker blood testing can help predict how World Health Organization (WHO) grade IV gliomas (malignant gliomas) might change or progress over time.

Key Dates

Start date
Oct 3, 2025
Status verified
Feb 2026
Primary completion
Oct 6, 2028
Completion
Oct 6, 2028

Study Design

Enrollment
15 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: Diagnostic (T2* MRI, blood sample collection)
    Patients undergo T2\* MRI over 10 minutes and blood sample collection during radiation therapy simulation, weekly during radiation therapy, and at 1- and 3- months post-radiation therapy in the absence of unacceptable toxicity. Patients also undergo standard MRI throughout the study.

Primary Outcome Measure

Relationship between T2 (observed)-weighted imaging (T2*) magnetic resonance imaging relation time and dimeric transferrin receptor expression [ Time Frame: Up to 3 months post-radiation therapy ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Iowa Health CareIowa CityIowa52245
John Buatti, MD
[email protected]
319-356-7590
John Buatti, MD
[email protected]
(319) 356-7590

Find similar trials in Iowa City, IA

By research site
University of Iowa Health Care· Iowa City, IA

Related Studies